Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exscientia Ltd ADR
(NQ:
EXAI
)
6.000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exscientia Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
August 18, 2024
Merging with a former rival will bolster its capabilities.
Via
The Motley Fool
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
August 15, 2024
EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Exscientia Business Update for Second Quarter and First Half 2024
August 15, 2024
From
Exscientia plc
Via
Business Wire
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
August 14, 2024
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...
Via
Talk Markets
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
August 14, 2024
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
August 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
August 11, 2024
The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
August 08, 2024
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
August 08, 2024
Operational complementarities expected to yield annual synergies of approximately $100 million
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.
Via
Talk Markets
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under...
Via
Talk Markets
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
July 18, 2024
From
Exscientia plc
Via
Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery
July 10, 2024
From
Exscientia plc
Via
Business Wire
3 Small-Cap Stocks With Explosive 2X Growth Potential
July 08, 2024
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.
Via
InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read
Via
Talk Markets
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 25, 2024
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Exscientia p.l.c. (EXAI)
June 24, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
EXAI FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
June 24, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 24, 2024
From
The Schall Law Firm
Via
Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
EXSCIENTIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Exscientia plc. and Encourages Investors to Contact the Firm
June 21, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia
June 21, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
June 21, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 21, 2024
From
Schall Law
Via
GlobeNewswire
EXSCIENTIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Exscientia p.l.c. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – EXAI
June 20, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm
June 18, 2024
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GoodRx, Exscientia, Malibu Boats, and Equinix and Encourages Investors to Contact the Firm
June 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
The global
Via
Talk Markets
Lowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
June 17, 2024
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.